Hancock Jaffe Laboratories Inc.

5.89-0.4600-7.24%Vol 283.97K1Y Perf -41.14%
Apr 15th, 2021 16:00 DELAYED
BID5.81 ASK6.00
Open6.40 Previous Close6.35
Pre-Market- After-Market-
 - -%  - -
Target Price
28.00 
Analyst Rating
— 0.00
Potential %
375.38 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     43.61
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     45.24
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap50.09M 
Earnings Rating
Neutral
Price Range Ratio 52W %
2.31 
Earnings Date
6th Apr 2021

Today's Price Range

5.856.40

52W Range

5.5520.25

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-15.25%
1 Month
-16.57%
3 Months
-31.03%
6 Months
-38.93%
1 Year
-41.14%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
HJLI5.89-0.4600-7.24
AAPL134.502.47001.87
GOOG2 296.6641.82001.85
MSFT259.503.91001.53
XOM56.98-0.3400-0.59
WFC42.240.25000.60
JNJ160.390.47000.29
FB307.825.00001.65
GE13.55-0.1300-0.95
JPM152.170.96000.63
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.00
0.03
0.12
3.13K
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
-
-24 247.00
-22 977.40
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-67.08
-
Earnings HistoryEstimateReportedSurprise %
Q03 2020--1.50-
Q02 2020--2.00-
Q01 2020--1.50-
Q03 2019--2.50-
Q02 2019--0.13-
Q01 2019-0.27-0.1351.85
Q03 2018-0.68-0.1380.88
----
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.340.00-
12/2021 FY-1.4262.43Positive
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume283.97K
Shares Outstanding8.50M
Trades Count1.93K
Dollar Volume4.68M
Avg. Volume597.53K
Avg. Weekly Volume303.54K
Avg. Monthly Volume473.36K
Avg. Quarterly Volume655.55K

Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) stock closed at 5.89 per share at the end of the most recent trading day (a -7.24% change compared to the prior day closing price) with a volume of 285.19K shares and market capitalization of 50.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 12 people. Hancock Jaffe Laboratories Inc. CEO is Robert A. Berman.

The one-year performance of Hancock Jaffe Laboratories Inc. stock is -41.14%, while year-to-date (YTD) performance is -31.91%. HJLI stock has a five-year performance of %. Its 52-week range is between 5.55 and 20.25, which gives HJLI stock a 52-week price range ratio of 2.31%

Hancock Jaffe Laboratories Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 8.06, a price-to-sale (PS) ratio of 191.44, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -136.48%, a ROC of -145.08% and a ROE of -238.34%. The company’s profit margin is -%, its EBITDA margin is -22 977.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Hancock Jaffe Laboratories Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Hancock Jaffe Laboratories Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Hancock Jaffe Laboratories Inc. is (0), with a target price of $28, which is +375.38% compared to the current price. The earnings rating for Hancock Jaffe Laboratories Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Hancock Jaffe Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Hancock Jaffe Laboratories Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.53, ATR14 : 0.65, CCI20 : -173.90, Chaikin Money Flow : -0.21, MACD : -0.58, Money Flow Index : 74.35, ROC : -10.08, RSI : 29.43, STOCH (14,3) : 1.92, STOCH RSI : 0.00, UO : 38.49, Williams %R : -98.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Hancock Jaffe Laboratories Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0
0 (0.00 %)
0 (0.00 %)
Hold
0
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0
0 (0.00 %)
0 (0.00 %)
Strong Sell
0
0 (0.00 %)
0 (0.00 %)
Summary Rating-Strong Buy
1.00
Strong Buy
1.00

Hancock Jaffe Laboratories Inc.

Hancock Jaffe Laboratories Inc is a medical device company. It develops and sells biological tissue solutions to treat patients with coronary, vascular, end-stage renal and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices. Its key products include Bioprosthetic Heart Valve, CoreoGraft- Bypass Graft, and the Venous Valve.

CEO: Robert A. Berman

Telephone: +1 949 261-2900

Address: 70 Doppler, Irvine 92618, CA, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

37%63%

Bearish Bullish

57%43%

News

Stocktwits